Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment

Urszula Szlendak(Instytut Hematologii i Transfuzjologi), Jacek Nowak(Instytut Hematologii i Transfuzjologi), Bożena Katarzyna Budziszewska(Instytut Hematologii i Transfuzjologi), Justyna Spychalska(Instytut Hematologii i Transfuzjologi), Elżbieta Patkowska(Institute for Transfusion Medicine), Joanna Drozd‐Sokołowska(Medical University of Warsaw)

Polskie Archiwum Medycyny Wewnętrznej

June 6, 2022

10.20452/pamw.16271

Cited by 37

Related Papers

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|390

DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with Cataplexy in Europe

|SLEEP|2014|200

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy

|Blood|2022|129

Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity

|SLEEP|2016|84

Congenital disorder of glycosylphosphatidylinositol (GPI)-anchor biosynthesis—The phenotype of two patients with novel mutations in the PIGN and PGAP2 genes

|European Journal of Paediatric Neurology|2016|51